{"id":"https://genegraph.clinicalgenome.org/r/6a5e373f-4215-407a-aab1-75d6a2b0bd67v1.2","type":"EvidenceStrengthAssertion","dc:description":["*ADAT3* encodes the non-catalytic subunit of the heterodimeric ADAT2/ADAT3 tRNA deaminase complex, which catalyzes adenosine-to-inosine modification at position 34 of transfer RNAs, essential for accurate protein translation and decoding of C-ending codons. Biallelic loss-of-function variants in *ADAT3* cause autosomal recessive intellectual disability through deficient wobble inosine modification, leading to impaired protein synthesis that particularly affects neurodevelopment.\n\nFive different genetic variants identified so far include the highly recurrent p.Val144Met founder mutation found in over 90% of total reported patients, with 55 patients from 29 consanguineous families, predominantly from Middle Eastern countries (Alazami et al, PMID: 23620220; Del-Pozo-Rodriguez et al, PMID: 40120092), along with two missense variants (p.Ala196Val, p.Ala196Leu) (Ramos et al. PMID: 32763916; Thomas et al. PMID: 31687266), one frameshift variant (8-bp duplication causing p.Glu36Glyfs44) (Chaleshtori, et al. PMID: 29796286), and one nonsense variant (p.Gln274*) (PMID: 32763916), found in homozygous and compound heterozygous states. Strong segregation evidence with maximum points awarded demonstrates co-segregation of variants with disease phenotype across multiple affected families. Clinical features consistently include intellectual disability (100%) and absent or severely delayed speech, with variable features such as microcephaly, seizures, muscle tone defects, and other features such as failure to thrive, strabismus, and dysmorphic facial features. \nFunctional studies demonstrate that *ADAT3* variants reduce enzymatic activity, protein stability, and tRNA modification in patient cells, with rescue experiments confirming that catalytic function is essential for proper neuronal migration and cortical development.\n\nIn summary, there is moderate evidence supporting the relationship between *ADAT3* and autosomal recessive intellectual disability-strabismus syndrome. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panels on August 5, 2025 (SOP Version 11). Gene Clinical Validity Standard Operating Procedures (SOP) - SOP11\n","*ADAT3* encodes the non-catalytic subunit of the heterodimeric ADAT2/ADAT3 tRNA deaminase complex, which catalyzes adenosine-to-inosine modification at position 34 of transfer RNAs, essential for accurate protein translation and decoding of C-ending codons. Biallelic loss-of-function variants in *ADAT3* cause autosomal recessive intellectual disability through deficient wobble inosine modification, leading to impaired protein synthesis that particularly affects neurodevelopment.\n\nFive different genetic variants identified so far include the highly recurrent p.Val144Met founder mutation found in over 90% of total reported patients, with 55 patients from 29 consanguineous families, predominantly from Middle Eastern countries (Alazami et al., PMID: 23620220; Del-Pozo-Rodriguez et al., PMID: 40120092), along with two missense variants (p.Ala196Val, p.Ala196Leu) (Ramos et al., PMID: 32763916; Thomas et al., PMID: 31687266), one frameshift variant (8-bp duplication causing p.Glu36Glyfs44) (Chaleshtori et al., PMID: 29796286), and one nonsense variant (p.Gln274*) (PMID: 32763916), found in homozygous and compound heterozygous states. Strong segregation evidence with maximum points awarded demonstrates co-segregation of variants with disease phenotype across multiple affected families. Clinical features consistently include intellectual disability (100%) and absent or severely delayed speech, with variable features such as microcephaly, seizures, muscle tone defects, and other features such as failure to thrive, strabismus, and dysmorphic facial features. \n\nFunctional studies demonstrate that *ADAT3* variants reduce enzymatic activity, protein stability, and tRNA modification in patient cells, with rescue experiments confirming that catalytic function is essential for proper neuronal migration and cortical development.\n\nIn summary, there is moderate evidence supporting the relationship between *ADAT3* and autosomal recessive intellectual disability-strabismus syndrome. While more evidence is needed to establish this relationship definitively, no convincing contradictory evidence has emerged. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on September 16, 2025 (SOP Version 11).\n"],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6a5e373f-4215-407a-aab1-75d6a2b0bd67","GCISnapshot":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc","calculatedEvidenceStrength":"Moderate","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2025-09-15T22:00:00.000Z","2025-09-16T16:00:00.000Z"],"role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-10-01T10:23:22.745Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/62078658-a984-49b8-9de2-e7b29d3f135e","type":"EvidenceLine","dc:description":"Functional evidence was not scored because points were awarded to individual variants.","calculatedScore":1,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/96882542-82ee-4135-8577-baaa6c1e1c70","type":"FunctionalAlteration","dc:description":"Severe ADAT3 protein depletion in patient lymphoblastoid cell lines (Western blot), selective loss of I34 tRNA modification particularly affecting tRNA-Ala-AGC family (mim-tRNA-seq), reduced abundance of ADAT target tRNAs with inverse correlation between I34 loss and tRNA stability, and 68-76% reduction in enzymatic activity for damaging variants (V144M, A196L) in in vitro deamination assays.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/40120092","rdfs:label":"ADAT3 functional analysis in patient lymphoblastoid cell lin"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c4b66ff1-2d91-4992-a7d0-9cc8a32572a8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/88db3dc5-5176-4f8d-ac03-7a303002f665","type":"Finding","dc:description":"Wild-type ADAT3 successfully rescues neuronal migration defects in a dose-dependent manner, while only 1 of 3 patient variants (A196V) can rescue the phenotype, directly correlating with enzymatic activity levels. The two variants with severely impaired enzymatic activity (V144M with 68% reduction, A196L with 76% reduction) fail to rescue, demonstrating that catalytic function is essential for ADAT3's role in neuronal migration.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/40120092","rdfs:label":"Mouse cortical neuron migration rescue assay","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3f3180e-4b20-4ba1-a600-58f272d80e21_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a3f3180e-4b20-4ba1-a600-58f272d80e21","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32763916","rdfs:label":"II:1 ","ageType":"AgeAtReport","ageUnit":"Years","ageValue":13,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/78c7810f-b582-4f6f-b1fd-f3c1483bbc35","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_079834.4(SCAMP4):c.-41-2112C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9054619"}},{"id":"https://genegraph.clinicalgenome.org/r/e4e799e7-7860-4e78-a0ba-b04a33adb4e0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_079834.4(SCAMP4):c.-41-2345C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA403171634"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001999","obo:HP_0001344","obo:HP_0002197","obo:HP_0000490"],"previousTesting":false,"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/43afb681-e912-4464-ae1f-796d1943ab8e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32763916","allele":{"id":"https://genegraph.clinicalgenome.org/r/78c7810f-b582-4f6f-b1fd-f3c1483bbc35"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/4e54e2f5-d39d-447c-8312-8aa2806504d3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32763916","allele":{"id":"https://genegraph.clinicalgenome.org/r/e4e799e7-7860-4e78-a0ba-b04a33adb4e0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/43afb681-e912-4464-ae1f-796d1943ab8e","type":"EvidenceLine","dc:description":"This variant in ADAT3 is also known as c.820C>T, p.Q274*","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/43afb681-e912-4464-ae1f-796d1943ab8e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/43afb681-e912-4464-ae1f-796d1943ab8e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The c.820C>T, Q274* variant introduces a premature stop codon that truncates nearly half of the ADAT3 deaminase domain, resulting in severely reduced full-length protein levels. This truncated protein exhibits defective nuclear localization that cannot be rescued by ADAT2 overexpression, effectively eliminating functional ADAT2/3 complex formation. While deaminase activity was not directly measured for Q274* alone (only tested in compound heterozygous patient cells), the severe structural truncation strongly suggests little to no catalytic activity.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/4e54e2f5-d39d-447c-8312-8aa2806504d3","type":"EvidenceLine","dc:description":"While A196V shows clear protein interaction and localization defects when tested individually, all functional studies (wobble inosine modification, adenosine deaminase activity, and rescue experiments) were performed using compound heterozygous patient cells (A196V/Q274*), individual pathogenic contribution of A196V remains experimentally unconfirmed.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e54e2f5-d39d-447c-8312-8aa2806504d3_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.1},{"id":"https://genegraph.clinicalgenome.org/r/196260f0-6306-4323-b45f-70d1af9550b1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/196260f0-6306-4323-b45f-70d1af9550b1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31687266","rdfs:label":"Subject 1 ","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/81b622ac-435a-45af-8060-9828fae52e55","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_079834.4(SCAMP4):c.-41-2346_-41-2345delinsTT","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658799105"}},{"id":"https://genegraph.clinicalgenome.org/r/e4e799e7-7860-4e78-a0ba-b04a33adb4e0"}],"detectionMethod":"Exome sequencing was performed on Subject 2, the sibling of Subject 1. Sanger sequencing confirmed the results in Subject 2 and their parents, and was subsequently performed on Subject 1 for validation.","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0001252","obo:HP_0002020","obo:HP_0000252","obo:HP_0000565","obo:HP_0001508","obo:HP_0011968","obo:HP_0002474"],"previousTesting":false,"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/4c78d0e1-39b1-4980-983c-882f72b52c7b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31687266","allele":{"id":"https://genegraph.clinicalgenome.org/r/81b622ac-435a-45af-8060-9828fae52e55"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}},{"id":"https://genegraph.clinicalgenome.org/r/f2fcf5e9-dc10-4903-88c4-417541510c66_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31687266","allele":{"id":"https://genegraph.clinicalgenome.org/r/e4e799e7-7860-4e78-a0ba-b04a33adb4e0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}]},{"id":"https://genegraph.clinicalgenome.org/r/4c78d0e1-39b1-4980-983c-882f72b52c7b","type":"EvidenceLine","dc:description":"This variant in ADAT3 is also known as p.Ala196Leu (A196L). \n","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c78d0e1-39b1-4980-983c-882f72b52c7b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4c78d0e1-39b1-4980-983c-882f72b52c7b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"A196L causes severe loss of function demonstrated by 76% reduction in enzymatic activity (in vitro assays), reduced protein solubility in expression studies. In patient-derived lymphoblastoid cell lines carrying compound heterozygous A196V/A196L variants, severe protein depletion and selective loss of I34 tRNA modification were observed, though these cellular defects cannot be attributed specifically to A196L alone due to the compound heterozygous state.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f2fcf5e9-dc10-4903-88c4-417541510c66","type":"EvidenceLine","dc:description":"This variant in ADAT3 is also known as p.Ala196Val (A196V). ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f2fcf5e9-dc10-4903-88c4-417541510c66_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/7a9357c4-670e-498d-8e50-e58b08cff6cc_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4c3aea3c-2cac-4ad1-b0eb-076daa5edd90_proband_segregation","type":"FamilyCosegregation","dc:description":"There are over 20 segregations from Figure 1D, and the group decided to apply the maximum available segregation points.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23620220","rdfs:label":"IDS_Fam1 to IDS_Fam8","estimatedLodScore":20.03,"family":{"id":"https://genegraph.clinicalgenome.org/r/4c3aea3c-2cac-4ad1-b0eb-076daa5edd90","type":"Family","rdfs:label":"IDS_Fam1 to IDS_Fam8","member":{"id":"https://genegraph.clinicalgenome.org/r/e6bdfef1-65d6-4d0f-9c4f-0003dcdc43f4","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23620220","rdfs:label":"IDS_Fam7 _V:2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"allele":{"id":"https://genegraph.clinicalgenome.org/r/17e28d31-89e0-4028-ad65-a036d4270b5a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_079834.4(SCAMP4):c.-41-2502G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA186057"}},"detectionMethod":"Primary Detection Methods: Autozygosity Mapping and Linkage Analysis to narrow down to 19p13.3. Exam Sequencing and confirmed via Direct Sanger sequencing. ","firstTestingMethod":"Linkage analysis","phenotypeFreeText":"Intellectual disability, Strabismus, Esotropia, Failure to thrive ","previousTesting":false,"secondTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/a447b48b-fb2c-40c0-af9b-001d2ca6a4a0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23620220","allele":{"id":"https://genegraph.clinicalgenome.org/r/17e28d31-89e0-4028-ad65-a036d4270b5a"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"While other features like microcephaly, hypotonia, spasticity, and epilepsy were present in multiple families, they were not consistently present across all families, showing variable expressivity. Brain MRI findings were also variable, ranging from normal to various abnormalities including arachnoid cysts, mild brain atrophy, and ventricular changes.","phenotypeNegativeAlleleNegative":35,"phenotypePositiveAllelePositive":27,"phenotypes":["obo:HP_0001508","obo:HP_0000565","obo:HP_0001249","obo:HP_0000486"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/e6bdfef1-65d6-4d0f-9c4f-0003dcdc43f4"},"publishedLodScore":5,"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/e6bdfef1-65d6-4d0f-9c4f-0003dcdc43f4_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e6bdfef1-65d6-4d0f-9c4f-0003dcdc43f4"},{"id":"https://genegraph.clinicalgenome.org/r/a447b48b-fb2c-40c0-af9b-001d2ca6a4a0","type":"EvidenceLine","dc:description":"This variant in ADAT3 is published as c.382G>A, p.Val128Met and it is also known as p.Val144Met (V144M).","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a447b48b-fb2c-40c0-af9b-001d2ca6a4a0_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/a447b48b-fb2c-40c0-af9b-001d2ca6a4a0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"V144M causes severe loss of function demonstrated by 68% reduction in enzymatic activity (in vitro assays), severe protein depletion in patient-derived lymphoblastoid cell lines (Western blot), and selective loss of I34 tRNA modification with reduced tRNA abundance in patient cells. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/7571fcf0-7e51-4986-99b0-3cf1bf4d733b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7571fcf0-7e51-4986-99b0-3cf1bf4d733b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29796286","rdfs:label":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"allele":{"id":"https://genegraph.clinicalgenome.org/r/faf7d9cf-0367-4ba4-8f91-de3f327959f6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_079834.4(SCAMP4):c.-41-2833_-41-2826dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA9054484"}},"detectionMethod":"Targeted sequencing of 12 genes associated with microcephaly (SLC25A19, STIL, ASPM, CEP135, MCPH1, CDK5RAP2, CENPJ, CEP152, WDR62, ZNF335, ADAT3, and EFTUD2)","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0007018","obo:HP_0000252","obo:HP_0100543","obo:HP_0000750","obo:HP_0012758"],"previousTesting":false,"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/55052d1d-e821-45d3-8bf7-98c8cd3355e2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29796286","allele":{"id":"https://genegraph.clinicalgenome.org/r/faf7d9cf-0367-4ba4-8f91-de3f327959f6"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/55052d1d-e821-45d3-8bf7-98c8cd3355e2","type":"EvidenceLine","dc:description":"This variant in ADAT3 is known as c.99_106dup, p.(Glu36Glyfs*44) . Points capped at 2.0 due to consanguinity in the study.","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/55052d1d-e821-45d3-8bf7-98c8cd3355e2_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":8.7}],"evidenceStrength":"Moderate","sequence":11903,"specifiedBy":"GeneValidityCriteria11","strengthScore":10.7,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Y5RaR_V0aGE","type":"GeneValidityProposition","disease":"obo:MONDO_0014119","gene":"hgnc:25151","modeOfInheritance":"obo:HP_0000007"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_7a9357c4-670e-498d-8e50-e58b08cff6cc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}